Glaxosmithkline Pharmaceuticals Q2 Results FY27: PAT Jumps 30.44% to Rs 335.88 Cr, Revenue Rs 1,183.57 Cr

Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Q2 Results FY27 announced on 3 November 2026, covering the company's financial performance for the July to September quarter. The company reported Consolidated revenue of Rs 1,183.57 Cr and PAT of Rs 335.88 Cr. Glaxosmithkline Pharmaceuticals Q2 Results FY27 mark a 20.78% rise in revenue and a 30.44% rise in net profit over the same quarter last year, and the results date and the consolidated results basis apply to every figure that follows.

This Glaxosmithkline Pharmaceuticals Q2 Results review is a results analysis of the numbers filed with NSE and BSE. It covers the financial highlights, the business drivers supplied for the quarter, the FY27 outlook and the risks to watch, and it starts with the table of key figures below.

Click Here – Get Free Investment Predictions

Glaxosmithkline Pharmaceuticals Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 1183.57 Cr	Rs 979.94 Cr	+20.78% YoY
Operating Profit	Rs 402.07 Cr	Rs 335.73 Cr	+19.76% YoY
Net Profit (PAT)	Rs 335.88 Cr	Rs 257.49 Cr	+30.44% YoY

Source: company filing for Glaxosmithkline Pharmaceuticals Q2 Results FY27, 3 November 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Glaxosmithkline Pharmaceuticals Q2 Results: What Stands Out

• Revenue Rs 1,183.57 Cr: Sales were up 20.78% from Rs 979.94 Cr a year earlier, a double-digit YoY growth reading on the Consolidated basis.
• Net profit Rs 335.88 Cr: PAT rose 30.44% from Rs 257.49 Cr, a faster rise than revenue, as reported in Glaxosmithkline Pharmaceuticals Q2 Results FY27.
• Operating Profit Rs 402.07 Cr: The line rose 19.76% from Rs 335.73 Cr, slightly behind the pace of revenue growth in the same quarter.
• Net profit margin 28.4%: It improved from 26.3% in the comparison quarter, so net profit grew faster than sales.
• Return on equity 48.76%: This FY26 figure frames the performance analysis that follows, where each line is compared year on year.

Glaxosmithkline Pharmaceuticals Q2 Results FY27: Performance Analysis

Glaxosmithkline Pharmaceuticals Q2 Results FY27 show Consolidated revenue of Rs 1,183.57 Cr, net profit of Rs 335.88 Cr and Operating Profit of Rs 402.07 Cr for July to September 2026. All three lines rose year on year, with net profit growing the fastest at 30.44%.

Within Glaxosmithkline Pharmaceuticals Q2 Results FY27, revenue added Rs 203.63 Cr over the same quarter last year, while net profit added Rs 78.39 Cr and Operating Profit added Rs 66.34 Cr. This YoY growth in net profit outpaced the revenue gain, which is the main point of the results analysis.

The Glaxosmithkline Pharmaceuticals Q2 Results figures also show how the lines sit against each other. Net profit of Rs 335.88 Cr equals 28.4% of revenue, up from 26.3% a year earlier, and the quarterly results lead to the question of what drove this, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis points first to revenue, which grew 20.8% year on year to Rs 1,183.57 Cr in the latest quarter. The supplied data confirms this rise but does not establish the specific cause behind it.

Net Profit Growth – Net profit rose 30.4% year on year to Rs 335.88 Cr, which is the second driver visible in Glaxosmithkline Pharmaceuticals Q2 Results FY27. It outpaced revenue growth, so profit moved ahead of sales in the quarterly results.

Net Profit Margin – Net profit margin improved to 28.4% from 26.3% in the comparison quarter, which means each rupee of revenue converted into more net profit than a year earlier.

FY27 Outlook After Glaxosmithkline Pharmaceuticals Q2 Results

The FY27 full-year picture will depend on the quarters that follow Glaxosmithkline Pharmaceuticals Q2 Results FY27 and on the disclosures the company files later in the year. Later filings will show whether the net profit growth of 30.44% in this quarter carries into the second half.

For readers tracking FY27, the figures to compare in each filing are revenue, Operating Profit and net profit on the same Consolidated basis. The Univest Screener lets investors line up these filed numbers across quarters, so the next results analysis starts from a like-for-like base, and the risks below show what to keep in view.

Key Risks to Watch After Glaxosmithkline Pharmaceuticals Q2 Results FY27

Return on Equity Moved Lower

Return on equity declined to 48.76% in FY26 from 49.43% in FY25. Even with strong YoY growth in the latest quarter, the full-year ratio was lower, a point readers of Glaxosmithkline Pharmaceuticals Q2 Results FY27 may want to track.

Return on Capital Employed Eased

Return on capital employed declined to 66.79% in FY26 from 67.64% in FY25. The change is small, but it sits alongside the return on equity move, so both ratios are worth checking in the next filing.

Annual Earnings Record

The multi-year annual record shows lower per-share profit in FY26 than in FY22. That longer history gives a more cautious backdrop to the 30.44% net profit rise in this quarter.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Glaxosmithkline Pharmaceuticals Q2 Results FY27 show Consolidated revenue of Rs 1,183.57 Cr and net profit of Rs 335.88 Cr, both higher than a year earlier. The quarterly results point to faster profit growth than revenue growth in the consolidated results. Readers can follow Glaxosmithkline Pharmaceuticals Q2 Results updates on the Univest app, and should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Glaxosmithkline Pharmaceuticals Q2 Results FY27

What are Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. Glaxosmithkline Pharmaceuticals Q2 Results FY27 cover July to September 2026 on a Consolidated basis, with revenue of Rs 1,183.57 Cr and net profit of Rs 335.88 Cr, as summarised in the Quick Answer at the top of this article.

What is the results date for Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. The results were declared on 3 November 2026 for the July to September 2026 quarter, so the results date sits alongside the Consolidated figures described in the opening section of this article.

What revenue was reported in Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. Glaxosmithkline Pharmaceuticals reported revenue of Rs 1,183.57 Cr in the quarter, compared with Rs 979.94 Cr a year earlier, as the Financial Highlights table shows for the same Consolidated period.

What net profit was reported in Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. Net profit was Rs 335.88 Cr, against Rs 257.49 Cr in the same quarter last year, which means PAT rose 30.44% as listed in the Financial Highlights table.

How much YoY growth did revenue show in Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. Revenue grew 20.78% year on year, while Operating Profit rose 19.76% over the same period, so top-line growth was slightly ahead of that profit line, as the Performance Analysis explains.

Did net profit rise or fall in Glaxosmithkline Pharmaceuticals Q2 Results?

Ans. Net profit rose in Glaxosmithkline Pharmaceuticals Q2 Results, up 30.44% to Rs 335.88 Cr, which means it grew faster than revenue, a comparison covered in the Key Takeaways section.

What was the Operating Profit in Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. Operating Profit was Rs 402.07 Cr against Rs 335.73 Cr a year ago, so it rose 19.76%, alongside the revenue and net profit comparison given in the Performance Analysis section.

Are Glaxosmithkline Pharmaceuticals Q2 Results consolidated results or standalone results?

Ans. These are consolidated results, so the figures cover the company on a Consolidated basis, while the Financial Highlights and Performance Analysis sections use the same basis throughout.

What business factors shaped Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. Revenue growth of 20.8%, net profit growth of 30.4% and a net profit margin of 28.4% against 26.3% shaped the quarter, as the Key Business Factors section sets out.

What are the key risks after Glaxosmithkline Pharmaceuticals Q2 Results FY27?

Ans. The risks are the lower FY26 return on equity at 48.76% and return on capital employed at 66.79%, alongside the longer annual record, all covered in the Key Risks section.

What is the outlook after Glaxosmithkline Pharmaceuticals Q2 Results?

Ans. The outlook depends on the FY27 quarters that follow, so later filings will show whether revenue and net profit growth continue, as the Outlook section explains.

Where can I find the complete Glaxosmithkline Pharmaceuticals Q2 Results FY27 data?

Ans. The complete data sits in the Financial Highlights table above, while the Univest Screener lets readers compare the filed figures with earlier quarters, as noted in the Outlook section.